DMRA
Damora Therapeutics, Inc.
20.60$
+1.6%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 19 | Q1 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -44.4% | +228.0% | -36.6% | +90.4% | +13.1% | +5.4% | -5.9% | +6.3% | -11.9% | +0.0% | +57.7% | -15.2% | -31.7% | +286.3% | -37.6% | -57.2% | -21.4% | -22.1% | -91.7% | +60.0% | +12.5% | +11.1% | -30.0% | +871.4% | -83.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +28.1% | +62.5% | +1.3% | +28.9% | -13.6% | +12.9% | +3.8% | +30.8% | +3.6% | -23.4% | +2.6% | -3.8% | -21.9% | -68.5% | +8.5% | -11.0% | -25.5% | -40.4% | -7.8% | -32.7% | +116.1% | -3.3% | +13,856.8% | -88.0% | +7.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -38.2% | +13.1% | +1.8% | -11.0% | +133.8% | +72.9% | +34.4% | – | |
| – | +21.4% | +73.7% | +11.6% | +19.6% | -9.6% | +5.5% | +4.2% | +25.9% | +1.2% | -20.6% | -1.2% | -0.1% | -17.1% | -50.4% | +4.3% | -1.4% | -19.7% | -16.6% | -28.5% | -3.8% | +31.6% | -7.7% | +6,290.9% | -84.8% | +13.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -83.3% | -214.3% | – | +100.0% | – | – | -4.5% | +507.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.